RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
PT-141, also called bremelanotide, is a melanocortin receptor agonist studied in several clinical research settings. Early work examined erectile responses in men, while later trials evaluated desire and related distress in a defined population of premenopausal women. These are different research questions. This overview explains three original publications, including their limitations, without treating clinical study materials as interchangeable with research-use-only products. [1–3]
EARLY PT-141 RESEARCH IN MEN
Rosen and colleagues reported early clinical experiments in 2004 involving healthy men and men with erectile dysfunction who reported an inadequate response to sildenafil. The researchers measured erectile responses using RigiScan, an instrument that records changes in penile rigidity and circumference. They reported statistically significant responses under the experimental conditions. [1]
This was evidence of a physiological effect in a selected study setting. It was not a large, long-term demonstration of broad sexual wellbeing or effectiveness across all causes of erectile dysfunction. Instrument measurements also answer a different question from a participant's experience of desire, distress or relationship satisfaction.
The distinction matters when comparing this early work with later bremelanotide publications. A finding in men with a particular study eligibility profile cannot simply be transferred to women, and a finding about erectile response cannot be relabeled as a finding about desire.
WHAT THE RECONNECT TRIALS MEASURED
Kingsberg and colleagues published two randomized, double-blind, placebo-controlled phase 3 trials in 2019. Together, they randomized 1,267 premenopausal women with hypoactive sexual desire disorder. The controlled treatment period lasted 24 weeks. The two main outcomes concerned desire and distress related to low desire, assessed with specified questionnaires. [2]
Both trials found statistically significant improvements on these measures compared with placebo. However, the reported number of satisfying sexual events did not show a significant between-group difference. An accurate summary must preserve that distinction rather than describing every aspect of sexual function as improved. [2]
Nausea, flushing and headache occurred more often with bremelanotide. Most participants were white and recruited in the United States, which also matters when considering how broadly the findings apply. Palatin Technologies and AMAG Pharmaceuticals funded the studies. The results concern the enrolled population and study product, not an unrestricted enhancement claim. [2]
WHAT LONGER FOLLOW-UP ADDS
Simon and colleagues reported a 52-week open-label extension of RECONNECT. Of 856 eligible participants who completed the controlled phase, 684 entered the extension and 272 completed it. Participants and researchers knew that active treatment was being used; this was not another placebo-controlled comparison. [3]
The investigators reported maintained improvements in the measured symptoms among the observed participants and no new safety signals. Nausea, flushing and headache remained the most common treatment-related adverse events. Those observations add follow-up information, but the substantial loss of participants limits interpretation. [3]
People who choose to continue a study can differ from those who leave. Consequently, extension results cannot establish that the same benefit or tolerability would occur in everyone originally enrolled. Likewise, finding no new safety signal within a study does not rule out rare events or risks outside its eligibility criteria and observation period.
HOW TO READ THIS EVIDENCE
The three reports illustrate why study design, population and outcome should stay attached to every claim. A physiological response, a questionnaire score and a long-term follow-up observation are related but distinct kinds of evidence. Combining them into a universal claim would erase the limitations that make the findings interpretable.
Clinical publications also do not authenticate a separately supplied research batch. Identity, composition and analytical quality require their own documentation. These studies provide an educational record of bremelanotide development; they do not establish that any research-use-only vial is suitable for personal use.
REFERENCES
1. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research. 2004;16:135–142.
https://doi.org/10.1038/sj.ijir.3901200
2. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134:899–908.
https://doi.org/10.1097/AOG.0000000000003500
3. Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology. 2019;134:909–917.
https://doi.org/10.1097/AOG.0000000000003514